The interferon-gamma release assays (IGRAs) in the table below are eligible for procurement using Global Fund resources. To be eligible for procurement, IGRAs must meet at least one of the following standards: WHO policy recommendation; authorized for use by one of the Regulatory Authorities of the Founding Members of the Global Harmonization Task Force (GHTF), i.e., the regulatory authorities of the United States of America, the European Union, Japan, Canada and Australia, when stringently assessed (Class C and D); recommended for use by the Global Fund’s Expert Review Panel.
Click on any IGRA below for more information.
 |  |  |  |
QuantiFERON-TB Gold Plus (QFT-Plus) | WANTAI TB-IGRA | STANDARD E TB-Feron ELISA | RIDAScreen TB |
Type: ELISA-based | Type: ELISA-based | Type: ELISA-based | Type: ELISA-based |
Approval status: WHO policy recommendation; GHTF (US FDA) | Approval status: WHO policy recommendation | Approval status: WHO policy recommendation | Approval status: GHTF (EU IVDR) |
|
|
|
|
IGRA-TB | RIDAQuick TB | T-SPOT.TB | LIAISON QFT-Plus |
Type: Lateral Flow Fluorescence Immunoassay (FIA) with proprietary instrument | Type: Lateral Flow Immunoassay with proprietary instrument | Type: ELISPOT-based | Type: Chemiluminescence Immunoassay (CLIA) with proprietary instrument |
Approval status: GHTF (EU IVDR)
| Approval status: GHTF (EU IVDR) | Approval status: WHO policy recommendation; GHTF (US FDA) | Approval status: WHO policy recommendation; GHTF (US FDA) |
